Q2 EPS Estimate for Lexeo Therapeutics Increased by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for shares of Lexeo Therapeutics in a research note issued on Tuesday, May 27th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($0.45) per share for the quarter, up from their previous estimate of ($0.82). The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($1.61) EPS and FY2027 earnings at ($1.61) EPS.

Several other research analysts have also commented on LXEO. HC Wainwright reduced their price objective on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Chardan Capital cut their price target on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Royal Bank of Canada cut their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. JPMorgan Chase & Co. cut their price target on shares of Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, Leerink Partners cut their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Lexeo Therapeutics has an average rating of "Buy" and an average price target of $18.50.

Lexeo Therapeutics Stock Down 3.8%

Shares of NASDAQ LXEO traded down $0.11 during trading hours on Friday, hitting $2.76. 371,002 shares of the stock were exchanged, compared to its average volume of 502,297. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a market cap of $91.62 million, a PE ratio of -0.87 and a beta of 1.27. The firm has a fifty day moving average price of $3.03 and a 200-day moving average price of $4.62. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19).

Institutional Trading of Lexeo Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allostery Investments LP acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $46,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $69,000. SG Americas Securities LLC acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $72,000. Finally, Wells Fargo & Company MN increased its stake in shares of Lexeo Therapeutics by 49.9% in the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock worth $73,000 after acquiring an additional 3,714 shares during the period. Institutional investors and hedge funds own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.